FGF-23 serum levels does not show significant differences (p > 0.05) between SSc patients with early (21.17 ± 5.98 pg/ml), active (19.91 ± 5.07 pg/ml) and late (14 ± 6.86 pg/ml) NVC pattern. This evidence concerns the gene FGF23 and systemic sclerosis.